Last C$7.24 CAD
Change Today -0.06 / -0.82%
Volume 1.4K
COM On Other Exchanges
As of 3:59 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

cardiome pharma corp (COM) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/14/14 - C$12.02
52 Week Low
07/25/13 - C$2.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CARDIOME PHARMA CORP (COM)

Related News

No related news articles were found.

cardiome pharma corp (COM) Related Businessweek News

No Related Businessweek News Found

cardiome pharma corp (COM) Details

Cardiome Pharma Corp., a biopharmaceutical company, is engaged in the development and commercialization of cardiovascular therapies that enhance the life and health of patients. It offers BRINAVESS (vernakalant IV), for conversion of recent onset atrial fibrillation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company’s pre-clinical research and development focuses on modulating cellular proteins (ion channels) that gate the movement of ions across the cell membrane to control various functions, including contraction of muscles, secretion from glands, and responses to foreign bodies and inflammation. It has operations in Canada, the United States, Switzerland, and the United Kingdom. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

75 Employees
Last Reported Date: 03/27/14
Founded in 1986

cardiome pharma corp (COM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$508.3K
Chief Financial Officer
Total Annual Compensation: C$250.2K
Chief Operating Officer
Total Annual Compensation: C$220.3K
Chief Commercial Officer
Total Annual Compensation: C$390.0K
Corporate General Counsel
Total Annual Compensation: C$206.0K
Compensation as of Fiscal Year 2013.

cardiome pharma corp (COM) Key Developments

Cardiome Pharma Corp. Announces Closing of Senior, Secured Term Loan Facility

Cardiome Pharma Corp. announced the closing of a senior, secured term loan facility of up to $22 million to be made available to the company by MidCap Financial, LLC in two tranches with an interest rate of Libor plus 8%. Cardiome currently intends to use the proceeds of the first tranche of $12 million for working capital and general corporate purposes, including the expansion of its sales and marketing efforts for BRINAVESS® and AGGRASTAT® in Europe and other parts of the world, and for clinical development and regulatory costs of vernakalant (IV) and vernakalant (oral). The second tranche of up to $10 million is available to support a product or company acquisition. The loan carries a term of 48 months and is secured by substantially all of the assets of the company.

Cardiome Pharma Corp. Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-18-2014 03:30 PM

Cardiome Pharma Corp. Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-18-2014 03:30 PM. Venue: Toronto Board of Trade, 1 First Canadian Place (Corner of Bay and Adelaide), Toronto, ON M5X 1C1, Canada.

Cardiome Pharma Corp. Presents at JMP Securities Healthcare Conference, Jun-25-2014 03:00 PM

Cardiome Pharma Corp. Presents at JMP Securities Healthcare Conference, Jun-25-2014 03:00 PM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, United States. Speakers: William L. Hunter, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COM:CN C$7.24 CAD -0.06

COM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for COM.
View Industry Companies

Industry Analysis


Industry Average

Valuation COM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.7x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARDIOME PHARMA CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at